Skip to content

Genetic Investigations in Spontaneous Coronary Artery Dissection (SCAD)

Genetic Investigations in Spontaneous Coronary Artery Dissection (SCAD)

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01427179
Enrollment
2000
Registered
2011-09-01
Start date
2011-05-01
Completion date
2030-12-01
Last updated
2026-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

SCAD, Spontaneous Coronary Artery Dissection

Keywords

Spontaneous coronary artery dissection, SCAD

Brief summary

The purpose of the research is to identify mutations (defects in the genetic blueprint) that cause spontaneous coronary artery dissection (SCAD), in other words, spontaneous tears in blood vessels that supply the heart. Some mutations may be inherited (passed on) from a parent without an apparent blood vessel problem while others may develop for the first time in the affected person.

Detailed description

Study question: Do mutations within certain genes cause or confer susceptibility to spontaneous coronary artery dissection (SCAD)? Specific aims: 1. Create a genomic DNA and plasma biobank for individuals diagnosed with SCAD. 2. Identify inherited and de novo/new mutations that underlie SCAD. 3. Identify common genetic variants that confer risk for SCAD. Long term objective:Discover molecular and cellular mechanisms of SCAD and develop biomarkers to enable prediction and prevention. The purpose of the research is to identify mutations (defects in the genetic blueprint) that cause tears in blood vessels that supply the heart. Some mutations may be inherited (passed on) from a parent without an apparent blood vessel problem while others may develop for the first time in the affected person. The study includes individuals diagnosed with spontaneous coronary artery dissection, their biological parents, and relatives with fibromuscular dysplasia, arterial aneurysm, or arterial dissection. Adults with SCAD will be identified both retrospectively and prospectively.Confirmation of the diagnosis by review of coronary angiography will be required before proceeding with the informed consent process and blood or saliva sample procurement.

Interventions

None listed

Sponsors

Mayo Clinic
Lead SponsorOTHER

Study design

Observational model
FAMILY_BASED
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Men and women able to give informed consent and complete a 2 page questionnaire * Diagnosis of one or more episodes of spontaneous coronary artery dissection (SCAD) * Biological parent of individual with SCAD * Relative with fibromuscular dysplasia, arterial aneurysm, or arterial dissection

Exclusion criteria

* Lack of confirmation of SCAD diagnosis

Design outcomes

Primary

MeasureTime frameDescription
Identification of one or more gene mutation responsible for SCADBy end of studyVia GWAS and whole exome sequencing

Countries

United States

Contacts

CONTACTJake Nemgar
MayoSCAD@Mayo.edu5072663180
PRINCIPAL_INVESTIGATORSharonne N. Hayes, M.D.

Mayo Clinic

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 16, 2026